EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY 4.0

Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK)

Alita A Miller iD, Samir H Moussa iD, Sarah M McLeod iD

Antimicrobial Agents and Chemotherapy · 02.05.2024 · 68 (5)

DOI: 10.1128/aac.01698-23 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 02.05.2024. Verfasst von Alita A Miller und 2 weiteren Autor:innen. Beteiligte Einrichtung: Entasis Therapeutics Inc., an affiliate of Innoviva Specialty Therapeutics, Inc., Waltham, Massachusetts, USA. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections, Anti-Bacterial Agents, Colistin. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Entasis Therapeutics (Entasis Therapeutics Inc.).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acinetobacter baumannii-calcoaceticu s complex (ABC) causes severe, difficult-to-treat infections that are frequently antibiotic resistant. Sulbactam-durlobactam (SUL-DUR) is a targeted β-lactam/β-lactamase inhibitor combination antibiotic designed to treat ABC infections, including those caused by multidrug-resistant strains. In a global, pathogen-specific, randomized, controlled phase 3 trial (ATTACK), the efficacy and safety of SUL-DUR were compared to colistin, both dosed with imipenem-cilastatin as background therapy, in patients with serious infections caused by carbapenem-resistant ABC. Results from ATTACK showed that SUL-DUR met the criteria for non-inferiority to colistin for the primary efficacy endpoint of 28-day all-cause mortality with improved clinical and microbiological outcomes compared to colistin. This report describes the characterization of the baseline ABC isolates from patients enrolled in ATTACK, including an analysis of the correlation of microbiological outcomes with SUL-DUR MIC values and the molecular drivers of SUL-DUR resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial AgentsColistinMicrobial Sensitivity TestsSulbactamHumansMaleAcinetobacter calcoaceticusAzabicyclo CompoundsCilastatin, Imipenem Drug CombinationDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

Acinetobacter baumanniisulbactam-durlobactamβ-lactamase inhibitor

Substanzen

Anti-Bacterial AgentsAzabicyclo CompoundsCilastatin, Imipenem Drug CombinationColistindurlobactamSulbactam

Autor:innen und Institutionen

  • Entasis Therapeutics Inc., an affiliate of Innoviva Specialty Therapeutics, Inc., Waltham, Massachusetts, USA.

ORCID-Profile: Alita A Miller, Samir H Moussa, Sarah M McLeod

Förderung

  • Entasis Therapeutics (Entasis Therapeutics Inc.)

Zitieren

APA

Miller, A. A., Moussa, S. H., & McLeod, S. M. (2024). Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK). Antimicrobial Agents and Chemotherapy, 68(5). https://doi.org/10.1128/aac.01698-23

Vancouver

Miller AA, Moussa SH, McLeod SM. Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK). Antimicrobial Agents and Chemotherapy. 2024;68(5). doi:10.1128/aac.01698-23

BibTeX
@article{Miller2024,
  author = {Miller, Alita A and Moussa, Samir H and McLeod, Sarah M},
  title = {Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK)},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  volume = {68},
  number = {5},
  doi = {10.1128/aac.01698-23}
}
Kostenlos starten →